The decades-long quest to harness the power of messenger RNA to enhance cancer treatment has focused primarily on its value ...

Moderna (MRNA) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of ...

Moderna (MRNA) just began dosing patients in a Phase 1/2 study of mRNA-2808, its experimental T-cell therapy for advanced multiple myeloma. This effort highlights Moderna's growing emphasis on cancer ...

The observation that mRNA vaccines can sensitize tumors to immunotherapy has researchers eager to test how mRNA’s ability to activate the immune system could be harnessed in oncology.

Cancer patients who got an mRNA COVID vaccine within a few months of their immunotherapy lived longer than those who did not, health records show.

The federal government is cutting $500 million in research money for development of mRNA vaccines, which were widely used against the COVID-19 virus. Health Secretary Robert F. Kennedy Jr. said in a ...

Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...

ATLANTA — Moderna’s respiratory syncytial virus vaccine is safe and effective for adults who have received a solid organ ...

What Happened? Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 6.9% in the afternoon session after ongoing ...

The researchers found that mRNA-based COVID-19 vaccines could potentially help patients whose tumors don’t respond well to ...

The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing. “After a ...